查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球藥物輸送設備市場-2022-2029
市場調查報告書
商品編碼
1143392

全球藥物輸送設備市場-2022-2029

Global Drug Delivery Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

藥物輸送設備市場規模預計在 2021 年和 2029 年分別達到 780.9 億美元和 1248.3 億美元，在我預計的預測期內（2022-2029 年）以 5.6% 的複合年增長率增長。

藥物輸送裝置是用於通過特定給藥途徑將藥物和治療劑輸送到人體和各種系統的專用裝置。這些設備可以在醫療程序中使用一次或多次。

市場動態

藥物輸送設備市場的增長受到多種因素的推動，例如慢性病增加、生物製劑市場增長、技術進步和新產品推出。此外，全球冠狀病毒的爆發導致對藥品的需求激增，主要是針對傳染病。

預計慢性病患病率上升和政府資金增加將推動市場增長。

此類癌症的高發病率增加了研發工作，以開發新的藥物輸送系統，為患者提供更好的治療。在癌症治療藥物輸送中使用創新技術正在推動市場。對藥物自我給藥的日益增長的需求，例如在糖尿病等疾病中，正在推動無針給藥裝置的工業規模。

多年來，藥物輸送設備經歷了許多創新。多年來，藥物輸送領域出現了許多創新，並且沒有跡象表明很快就會放緩。一些改進了現有技術，如胰島素輸送裝置和吸入器，而另一些則解鎖了通過各種方式輸送藥物的新方法。該領域最好的創新者是美敦力和 Tandem Diabet Care 等大公司。此外，嶄露頭角的公司開始傳播，對治療劑新給藥方法的研究仍在繼續。

例如，總部位於辛辛那提的 Enable 2019 與賽諾菲合作，利用賽諾菲提供的多個分子開發計劃建立了一個長期的製造和供應結構。 Enable Injection 正在開發一種帶有 enFuse 的皮下給藥平台，該平台可用作身體貼片。 enFuse 使患者能夠在醫院外皮下輸送大劑量的治療藥物。這種體內藥物輸送平台具有與標準注射器和小瓶容器格式兼容的獨立藥物輸送系統。

藥物輸送設備變得越來越複雜，以簡化患者和醫療保健專業人員的藥物輸送。當今的許多設備都具有旨在促進自我管理和鼓勵患者遵守新方案的特殊功能。可穿戴設備通過促進積極的生活方式使我們更加方便。一些設備還提供連接功能以支持數字健康監測。

製藥行業的嚴格監管和低質量預計將阻礙市場增長。

當公司沒有意識到每個行業的質量和監管要求略有不同，並且配方產品的成分也受到略有不同的監管時，通常會出現最大的挑戰。

近年來，注射給藥領域的產品召回事件屢見不鮮。召回可能是自願發生的，也可能是在監管干預之後發生的。在開發過程中必須識別和解決可用性問題。可注射保留樣品測試過程中可見異物的存在可能導致嚴重的健康危害，例如身體功能的永久性損害、血管損傷或阻塞、局部炎症、靜脈炎、過敏反應、栓塞和感染。玻璃、矽和不銹鋼等無機物質的污染以及小瓶填充不完整也會導致注射劑的召回。

如果產品被召回，在召回和更換缺陷產品的過程中，企業和製造商可能會因更換或修復缺陷產品而遭受巨大損失。這些巨額虧損會影響一家公司的收入和市場份額，進而影響整個市場。關鍵挑戰不是技術本身，而是藥品和醫療設備這兩個不同領域的整合。

行業分析

針對全球藥物輸送市場，我們根據波特五力、監管分析、供應鏈分析、定價分析、未滿足需求等多種行業因素對市場進行深入分析。

COVID-19 影響分析

在 COVID-19 大流行期間，大多數製藥公司和政府都在努力為 COVID-19 患者提供高效的醫療服務，預計藥物輸送將在這方面發揮關鍵作用。我來了。在這個項目中，我們正在開發含有免疫增強劑和靶蛋白的仿生納米顆粒，並致力於鼻內免疫的原理。此外，COVID-19 已將多種產品（如注射給藥和霧化器）推向了前台市場。

由於氣霧劑療法會產生不被患者吸入並在呼氣時從設備中釋放出來的逸散性排放物，因此一些國際專業機構建議通過吸入器，尤其是霧化器進行藥物輸送。由於醫院將資源集中在治療 COVID-19 患者上，許多選擇性醫療程序被推遲或取消，其他產品的使用量有所下降。大流行為藥物輸送設備的開發和營銷開闢了新途徑。 COVID-19 可能會給藥物輸送設備行業帶來重大變化。這可能涉及轉向全新的藥物輸送設備製造系統，迫使許多公司採用新技術。

細分分析

注射給藥領域有望佔據全球給藥器械市場最大份額

根據研究報告，全球市場分為管理途徑、應用程序和最終用戶。

根據給藥途徑，市場細分為口服給藥、注射給藥、眼給藥、肺給藥、鼻給藥、經粘膜給藥、植入給藥和被動植入給藥。按用途分為傳染病、癌症、自身免疫性疾病、中樞神經系統疾病、呼吸系統疾病和糖尿病。根據最終用戶，它分為醫院、門診手術、家庭護理環境、診斷中心等。

由於技術進步和對生物製劑的需求增加，預計注射給藥領域將增長。隨著慢性疾病負擔的增加、益處和便利性的增加導致對自行注射器的需求增加，而生物製劑市場的增長導致對注射器的需求增加，預計可注射給藥裝置將迅速增長。自動注射器、筆式註射器和無針注射器等自我注射設備的推出，使得注射給藥 (IDD) 變得相對容易，讓患者無需醫療專業人員的幫助即可在家中給藥。現在您可以.

自動注射器是一種注射器或可穿戴設備，患者可以使用它在家中自行給藥。自動注射器讓慢性病患者能夠控制自己的治療計劃和治療環境，使他們能夠過上更加獨立和自由的社會、家庭和職業生活。

許多公司生產自動注射器。例如，2021 年 4 月 13 日，羅氏 (Roche) 的自註射 Xolair (omalizumab) 預充式註射器的生物製品許可申請補充材料獲得 FDA 批准，用於所有美國批准的適應症。 Xolair 是第一個也是唯一一個被 FDA 批准用於治療中度至重度持續性過敏性哮喘、慢性特發性蕁麻疹 (CIU) 和鼻息肉的生物製劑。

注射筆是用於通過皮膚給藥的裝置。筆式註射器的目的是使注射藥物更易於使用和使用。注射筆是為需要長期、連續服用激素或藥物以控製糖尿病等疾病的患者而設計的。有一次性和可重複使用的筆式註射器。該領域的市場細分日益發展，預計將刺激市場增長。

自動注射器是一種設計用於給藥特定劑量藥物的設備。大多數自動注射器是一次性使用的彈簧式註射器。自動注射器被簡單地設計用於由患者自行給藥或由未經培訓的人員給藥。注射部位取決於藥物，但通常是大腿或臀部。

預計可穿戴式註射器在預測期內將呈現最高的增長率。這些可穿戴注射器是一種輸送系統，可以佩戴在身體上，以在較長時間內通過皮下輸送更大劑量的藥物（大於 2mL）。可穿戴注射器用於大容量藥物、高粘度藥物製劑（如單克隆抗體）和長期、定時的藥物注射方案。當使用可穿戴注射器而不是讓患者進入醫療機構進行注射臨床協助時，體上註射器最有用。

區域分析

北美在全球藥物輸送設備市場佔有最大份額

根據調查結果，全球市場可分為 5 個區域：北美、南美、歐洲、中東和非洲、亞太地區和世界其他地區。

預計北美藥物輸送設備市場在預測期內將以最高的複合年增長率增長。在北美，美國的份額最大。心髒病是導致死亡的主要原因，給人們、社區、醫療保健提供者和系統帶來巨大負擔。該地區癌症發病率的上升也推動了該地區的市場增長。根據美國國家癌症研究所的數據，2019 年美國估計將有 1,735,350 例新診斷的癌症病例。因此，這些癌症患者通過注射器給予化療藥物。

預計在美國等國家/地區增加產品批准也將有助於市場增長。 2019 年 3 月，Aptar Pharma 獲得了美國 FDA 對鼻給藥裝置的批准。因此，美國慢性病患病率的增加以及與註射劑相關的新技術的採用可能有助於推動整個市場的增長。

新興經濟體和有利的監管程序是為主要歐洲市場參與者提供重要機會的一些關鍵因素。新興經濟體和有利的監管程序這是為該地區主要市場參與者提供重要機會的關鍵因素之一。

諸如癌症和糖尿病等慢性疾病的增加、對自動注射器（尤其是筆式註射器）的需求增加、技術進步、患者依從性以及德國主要製造商的存在等因素正在推動該市場在德國的增長。德國：我們支持增長。德國是所有主要製藥和生物技術公司的所在地。這些公司一直在努力推出新產品以增加其市場佔有率。

由於該地區的經濟高速增長，預計亞太地區將在預測期內呈現最快的增長率。日本、中國和印度等國家的高患者人數也導致各種最終用戶採用藥物輸送設備。該地區的增長主要是由於醫療機構中藥物輸送系統的高利用率、大部分人口的潛在報銷、慢性病（糖尿病和癌症）的增加、老年人口的增長以及對藥物代謝的日益了解。這部分是由於人們越來越傾向於個性化和定制的癌症治療。

在日本，越來越多地使用各種類型的藥物輸送裝置來輸送特定類型的藥物。 2019年12月，YpsoMate自動注射器進入日本市場，用於特立骨藥物的精準輸送。推動中國給藥裝置市場增長的主要因素是慢性病益處負擔的增加和便利性，導致對自動注射器的需求增加，從而導致對給藥裝置的需求增加。

競爭格局

給藥設備市場競爭激烈，由幾家主要參與者和新進入者組成。為市場增長做出貢獻的主要參與者包括Baxter International、Acromed AG、Medtronic、Becton、Dickinson and Company、F. Hoffmann-La Roche Ltd、Novartis AG、3M、Sanofi、Merck &Co., Inc、Pfizer Inc、Bayer AG、GlaxoSmithKline plc、Novosanis等。

主要參與者正在採取多種增長策略，例如產品發布、收購和合作夥伴關係，這有助於全球藥物輸送市場的增長。例如：

  • 2022 年 5 月，為生物技術和製藥業提供藥物輸送系統和醫療保健解決方案的公司 Gerresheimer AG 宣布投資總部位於美國的 Portal Instruments，該公司開發了下一代無針藥物輸送技術。兩家公司之間的合作將改變注射藥物管理，並有助於擴大 Gerresheimer 的創新藥物輸送技術平台。
  • 例如，2019 年，Novartis和 Shionogi（日本）在德國、英國和荷蘭等歐洲主要國家以及其他一些國家商業化了 Rizmoic (Naldemedine)，這是一種用於治療阿片類藥物引起的便秘的新療法。對於歐洲市場，我們簽訂了具有優先購買權的合同。
  • 2019 年 12 月，3M 簽署了一項協議，以約 6.5 億美元的價格將其藥物輸送業務出售給 Altaris Capital Partners, LLC 的關聯公司。

值得關注的主要公司

Pfizer Inc.：

概述Pfizer日本公司是一家活躍於生物技術領域的美國跨國製藥公司。成立於 1849 年，總部位於紐約市曼哈頓。它是心髒病學、腫瘤學、神經學和免疫學的各種疫苗和藥物的製造商。

產品組合

Nekject 預填充注射器。 Neject 是一種預填充一體式註射器，具有多種技術，例如耐熱和防潮。專為高效和簡單的藥物輸送而開發。

重大進展。 2022 年 1 月，Pfizer宣布與 Acuitas Therapeutics 達成開發和選擇協議，Acuitas Therapeutics 是一家開發脂質納米顆粒遞送系統和基於 m-RNA 的療法的公司。

全球藥物輸送設備市場報告提供大約 45 多個市場數據表、40 多個圖表和 180 頁內容。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
  • 驅動程序
    • 慢性病增加
    • 技術進步的增加
  • 約束因素
    • 質量和嚴格的監管
  • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 注射給藥
    • 自註射裝置
    • 注射筆
      • 自動注射器
      • 無針注射器
      • 穿戴式註射器
    • 其他
  • 鼻腔給藥
    • 粘膜霧化裝置
    • 霧化器
    • 鼻竇植入物
    • 噴鼻劑
    • 鼻腔沖洗器
    • 吸入器
    • 其他
  • 口服給藥
    • 微針膠囊
    • 口服片劑
    • 其他
  • 局部給藥
    • 透皮貼劑配方
    • 其他
  • 植入給藥
    • 主動植入給藥
    • 被動給藥
  • 肺內給藥
    • 霧化器
      • 噴射霧化器
      • 超聲波霧化器
      • 軟霧霧化器
    • 固定劑量吸入器
    • 乾粉吸入器
    • 其他
  • 眼科給藥
    • 藥用隱形眼鏡
    • 眼科插入物
    • 其他
  • 其他給藥系統
    • 重建交付系統
    • 輸液系統
    • 注入器
    • 室友
    • 無針系統
    • 其他

第 8 章. 按應用程序

  • 癌症
  • 感染
  • 呼吸系統疾病
  • 心血管疾病
  • 中樞神經系統疾病
  • 自身免疫性疾病
  • 糖尿病
  • 其他

第 9 章，最終用戶

  • 醫院
  • 診斷中心
  • 門診手術中心
  • 居家護理
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第 12 章公司簡介

  • Pfizer Inc.
    • 公司簡介
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Johnson & Johnson
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Becton, Dickinson and Company
  • Sanofi
  • Boehringer Ingelheim
  • Merck & Co., Inc.
  • Boston Scientific Corporation
  • Teva Pharmaceuticals Industries Ltd
  • AbbVie Inc.

第 13 章全球藥物輸送設備市場-DataM

簡介目錄
Product Code: DMMD1826

Market Overview

Drug Delivery Devices Market size was valued US$ 78.09 billion in 2021 and is estimated to reach US$ 124.83 billion by 2029, growing at a CAGR of 5.6% during the forecast period (2022-2029).

Drug delivery devices are specialized equipment used for the delivery of a drug or therapeutic agent through a specific route of administration into the human body and various systems. These devices can be used once or multiple times for medical treatments.

Market Dynamics

The drug delivery devices market growth is driven by several factors including, the rising prevalence of chronic diseases, growth in the biologics market, technological advancements, and new product launches. Also, due to the outbreak of coronavirus worldwide, there is a sudden increase in the demand for pharmaceutical drugs largely for infectious applications.

Increasing prevalence of chronic diseases and rising government funds are expected to drive the market growth.

Due to this high prevalence of cancer, increasing efforts are being made in R&D for the development of novel drug delivery systems for providing better treatment to patients. The use of innovative technologies in drug deliveries for cancer treatment is driving the market. The increasing need for self-administration of drugs as in the case of diseases such as diabetes has enhanced the size of the needle-free drug delivery devices industry.

The drug delivery device has seen plenty of innovation over the years. The drug delivery space has seen plenty of innovation over the years, and there are no signs of that slowing down any time soon. Improvements upon established technologies like insulin delivery devices and inhalers have been presented by some, while others have unlocked new ways of delivering drugs through a variety of means. Among the best innovations in the space are some of the heavy-hitting companies, like Medtronic and Tandem Diabetes Care. Some up-and-comers are beginning to make waves, too, while research continues to uncover new ways to deliver therapeutics.

For instance, Cincinnati-based Enable 2019 partnered with Sanofi to develop long-term manufacturing and supply arrangements using multiple molecule development programs provided by the company. Enable Injections is developing a subcutaneous drug delivery platform with the enFuse, which works as an on-body patch. enFuse enables patient-administered subcutaneous delivery of high-volume therapeutics outside of the hospital. The on-body drug delivery platform has a self-contained drug transfer system that is compatible with standard syringes and vial container formats.

To simplify drug delivery for patients and practitioners, drug-delivery devices are becoming more complex. Many of today's devices include special features designed to ease self-dosing and encourage patient adherence to novel regimens. Wearable devices are further easing use by promoting active lifestyles. And some devices are offering connectivity to support digital health monitoring.

Stringent regulations in pharma and poor quality are expected to hamper the market growth.

The quality and regulatory requirements in each industry are slightly different, and often the biggest challenges emerge when companies aren't aware that the constituent products of a combination product are also governed slightly differently.

In recent years, there has been numerous product recalls in the injectable drug delivery segment. Recalls can be voluntary or can result after the intervention of regulatory authorities. Usability issues must be identified and addressed during the development process. The presence of visible foreign matter during the testing of retention samples in injectable can cause severe health consequences such as permanent impairment of a body function, damage and/or obstruction of blood vessels, local inflammation, phlebitis, allergic response, and/or embolization in the body and infection. Other reasons due to which injectable face recalls are contamination from inorganic materials such as glass, silicone, and stainless steel, and also due to incomplete filling of vials.

If a product is recalled, the process of retrieving and replacing the defective product may cause a company or a manufacturer to incur huge losses associated with the replacement and fixing of faulty products. These huge losses will affect the revenue and the share of the company in the market, which in turn will impact the overall market. The key challenges are less about the technology itself and more about the integration of two distinct worlds pharma and medical device.

Industry Analysis

The global drug delivery devices market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis, pricing analysis and unmet needs.

COVID-19 Impact Analysis

At the outbreak of the COVID-19 pandemic, most pharmaceutical companies and governments are working toward offering efficient medical treatment to the COVID-19 patients, and drug delivery devices are expected to play a vital role in this context. The project is being worked toward developing principles for nasal immunization, developing a biomimetic nanoparticle provided with both immune enhancers and a targeting protein. In addition, COVID-19 has put the market in front of mind, with unparalleled demand for some products like Injectable drug delivery and nebulizer.

Considering that aerosol therapy generates fugitive emissions that are not inhaled by the patient and are released from the device during expiration, several international professional bodies have provided recommendations for drug delivery via inhalers and in particular, nebulizers. Because of the dramatic drop in elective medical procedures, many of which are being postponed or cancelled so that hospitals can focus resources on treating COVID-19 patients results in a drop in the use of other products. The pandemic is encouraging new avenues for drug delivery device development and marketing. COVID-19 has the potential to prompt a sea change in the drug delivery device industry. This may involve a shift towards entirely new drug delivery device manufacturing systems, forcing many companies to adopt new technology.

Segment Analysis

Injectable drug delivery segment is expected to hold the largest market share in global drug delivery devices market

According to the research report the global market is classified into route of administration, application, and end user.

Based on the route of administration, the market is subdivided into oral drug delivery, injectable drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, implantable drug delivery, and passive implantable drug delivery. based on application it is further divided into infectious diseases, cancer, autoimmune diseases, central nervous system disorders, respiratory diseases, and diabetes. based on end-user segment into hospitals, ambulatory surgery centers, home care settings, diagnostic centers, and others.

The injectable drug delivery segment is expected to grow with the increasing technological advancements and demand for biologics. The injectable drug delivery devices are projected to grow fastly due to the growing burden of chronic diseases, benefits, and convenience, which will lead to increased demand for self-injectors and growth in the biologics market, which will lead to increased demand for injectors. With the introduction of self-injection devices such as auto-injectors, pen-injectors, and needle-free injectors, the use of injectable drug delivery (IDD) has become relatively simple, allowing patients to administer drugs at home without the assistance of a medical professional.

Self-Injection devices are injections or wearable devices that a patient can use at home to administer medication to themselves. Self-injection devices give patients with chronic diseases control over their treatment schedule and treatment setting, allowing them more independence and freedom in their social, domestic, and professional lives.

Many companies are manufacturing self-injection devices. For instance, on April 13th, 2021, the FDA approved Roche company's supplemental Biologics License Application for Xolair(omalizumab) prefilled syringe for self-injection across all approved U.S. indications. Xolair is the first and only FDA-approved biologic for treating moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU), and nasal polyps.

An injector pen is a device used to administer medication through the skin. Injector pens are intended to make injectable medication more accessible and convenient to use. Pen injectors were created for patients who require a continuous long-term dosage of hormones and medications to manage conditions such as diabetes. They are available in both disposable and reusable forms. The increasing advancements are expected to fuel the market growth of this segment.

An autoinjector is a device designed to deliver a specific drug dose. The majority of autoinjectors are single-use, disposable spring-loaded syringes. Autoinjectors are designed to be simple and intended for self-administration by patients or administration by untrained personnel. The injection site varies depending on the drug, but it is usually in the thigh or buttocks.

Wearable injectors are expected to show at highest growth rate during the forecast period. These wearable injectors are delivery systems that attach to the body and allow for administering larger volumes (more than 2 mL) of drug subcutaneously over an extended period. Wearable injectors are used for high-volume medications, pharmaceutical formulations with high viscosities (e.g., monoclonal antibodies), and regimens requiring timed medication injection over a long period. On-body injectors are most useful when wearable injectors are used as an alternative to admitting the patient to a medical facility for clinical support of an injection.

Geographical Analysis

North America region holds the largest market share in the global drug delivery devices market

As per the research study, the global market is divided into majorly five regions such as North America, South America, Europe, the Middle East, Africa, Asia Pacific, and the Rest of the world.

The drug delivery devices market in North America is estimated to grow at a highest CAGR during the forecast period. The United States owns the largest share of the market in the North American region. Heart disease is a leading cause of death that creates an enormous burden on people, communities, and healthcare providers and systems. The rising prevalence of cancer in the region is also driving the growth of the market in the region. According to the National Cancer Institute, 2019, there were an estimated 1,735,350 new cases of cancer that were being diagnosed in the United States. Therefore, chemotherapy drugs are being delivered to these cancer patients through injectable devices.

In addition, growing product approval in countries such as the U.S. is also expected to contribute to market growth. In March 2019, Aptar Pharma received U.S. FDA approval for nasal drug delivery devices. Hence, the increasing prevalence of chronic diseases and the adoption of new technologies related to injectables in the United States may help in propelling the growth of the overall market.

Developed economies and favorable regulatory procedures are some of the principal factors providing huge opportunities for the major market players in the Europe. Developed economies and favorable regulatory procedures are some of the principal factors providing huge opportunities for the major market players in the region.

Factors such as the increasing prevalence of chronic diseases such as cancer and diabetes, increased demand for self-injection devices particularly pen injectors, technological advancements, patient compliance, and the presence of key market players in Germany are driving the growth of this market in the country. Germany has the presence of all the major pharmaceuticals and biotechnology companies. The companies are constantly taking initiatives to introduce new products in order to grow their presence in the market.

The Asia Pacific is expected to experience the fastest growth rate during the forecast period owing to high economic growth in the region. Moreover, a large patient pool in countries like Japan, China, and India is also leading to the adoption of drug delivery devices by various end-users. The growth in the region is mainly attributed to higher usage of drug delivery systems in healthcare facilities, availability of reimbursement for the majority of the population, increasing prevalence of chronic diseases (diabetes and cancer), growing geriatric population, increased understanding of drug metabolism and increased preference for individual and customized therapy, especially for cancer.

In Japan, different types of drug delivery devices are coming into use for delivering specific types of drugs. In December 2019, YpsoMate autoinjector entered the Japanese market for accurate delivery of Teribone drug. The major factors attributing to the growth of the Chinese drug delivery devices market are the growing burden of chronic diseases benefits, and convenience, leading to increased demand for self-injectors leading to increased demand for drug delivery devices.

Competitive Landscape

The drug delivery devices market is highly competitive and consists of several major players and the emergence of new players in the market. Some of the key players which are contributing to the growth of the market are Baxter International, Acromed AG, Medtronic, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Novartis AG, 3M, Sanofi, Merck & Co., Inc, Pfizer Inc, Bayer AG, GlaxoSmithKline plc, Novosanis, among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the global market for drug delivery devices. For instance,

  • In May 2022, Gerresheimer AG, company providing drug delivery system and healthcare solutions for biotech, pharmaceuticals announced its investment in Portal Instruments, U.S. based company that developed next generation needle free drug delivery technology. Their partnership will transform the injectable medicine's administration and help Gerresheimer expand its innovative drug delivery technologies platform.
  • For instance, in 2019, Novartis signed an agreement with Shionogi (Japan) to commercialize a new treatment, Rizmoic (Naldemedine) for Opiod-induced constipation in key European countries of Germany, the UK, and the Netherlands, with rights of first refusal for some other European markets.
  • In Dec 2019, 3M has entered into an agreement to sell its drug delivery business to an affiliate of Altaris Capital Partners, LLC for approximately $650 million.

Key Companies to Watch

Pfizer Inc.:

Overview: Pfizer Inc. is an American multinational pharmaceutical corporation that works in biotechnology domain also. It was founded in 1849 and headquartered in Manhattan, New York City. It is a manufacturer of various vaccines and medicines for cardiology, oncology, neurology, immunology.

Product Portfolio:

NEXJECT Prefilled Syringe: Nexject is a prefilled all in one syringe that contains multiple levels of technology such as temper-resistant and temper-evident. It is developed for efficient and easy delivery of medicines.

Key Developments: In Jan 2022, Pfizer announced its development and option agreement with Acuitas Therapeutics, company that develops lipid nanoparticle delivery system and m-RNA based therapeutics.

The global drug delivery devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising Prevalence of Chronic Diseases
    • 4.2.2. Increasing Technological Advancements
  • 4.3. Restraints
    • 4.3.1. Quality and Stringent Regulations
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. By COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Injectable Drug Delivery
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2021-2028
    • 7.2.3. Self-Injection Devices
    • 7.2.4. Pen Injectors
      • 7.2.4.1. Autoinjectors
      • 7.2.4.2. Needle-Free Injectors
      • 7.2.4.3. Wearable Injectors
    • 7.2.5. Others
  • 7.3. Nasal Drug Delivery
    • 7.3.1. Mucosal Atomization Devices
    • 7.3.2. Nebulizer
    • 7.3.3. Sinus Implant
    • 7.3.4. Nasal Spray
    • 7.3.5. Nasal Irrigation
    • 7.3.6. Insufflators
    • 7.3.7. Others
  • 7.4. Oral Drug Delivery
    • 7.4.1. Microneedle Capsule
    • 7.4.2. Buccal Tablets
    • 7.4.3. Others
  • 7.5. Topical Drug Delivery
    • 7.5.1. Transdermal Patches
    • 7.5.2. Others
  • 7.6. Implantable Drug Delivery
    • 7.6.1. Active Implantable Drug Delivery
    • 7.6.2. Passive Implantable Drug Delivery
  • 7.7. Pulmonary Drug Delivery
    • 7.7.1. Nebulizers
      • 7.7.1.1. Jet Nebulizers
      • 7.7.1.2. Ultrasonic Nebulizers
      • 7.7.1.3. Soft Mist Nebulizers
    • 7.7.2. Metered-Dose Inhalers
    • 7.7.3. Dry Powder Inhalers
    • 7.7.4. Others
  • 7.8. Ocular Drug Delivery
    • 7.8.1. Drug-Coated Contact Lenses
    • 7.8.2. Ocular Inserts
    • 7.8.3. Others
  • 7.9. Other Drug Delivery Systems
    • 7.9.1. Reconstitution Delivery System
    • 7.9.2. Infusion System
    • 7.9.3. Infusors
    • 7.9.4. Intermates
    • 7.9.5. Needlefree systems
    • 7.9.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2021-2028
  • 8.3. Infectious Diseases
  • 8.4. Respiratory Diseases
  • 8.5. Cardiovascular Diseases
  • 8.6. Central Nervous System Disorders
  • 8.7. Autoimmune Diseases
  • 8.8. Diabetes
  • 8.9. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2027 and Y-o-Y Growth Analysis (%), 2021-2028
  • 9.3. Diagnostic Centers
  • 9.4. Ambulatory Surgery Centers
  • 9.5. Home Care Settings
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East & Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Pfizer Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Johnson & Johnson
  • 12.3. Novartis AG
  • 12.4. F. Hoffmann-La Roche AG
  • 12.5. Becton, Dickinson and Company
  • 12.6. Sanofi
  • 12.7. Boehringer Ingelheim
  • 12.8. Merck & Co., Inc.
  • 12.9. Boston Scientific Corporation
  • 12.10. Teva Pharmaceuticals Industries Ltd
  • 12.11. AbbVie Inc.

LIST NOT EXHAUSTIVE

13. Global Drug Delivery Devices Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Method of Fixation
  • 13.3. Contact Us